The Current Ratio as of December 2024 (TTM) for Prelude Therapeutics Incorporated (PRLD) is 7.04

According to Prelude Therapeutics Incorporated’s latest financial reports and current stock price. The company's current Current Ratio is 7.04. This represents a change of -24.54% compared to the average of 9.32 of the last 4 quarters.

Prelude Therapeutics Incorporated (PRLD) Historical Current Ratio (quarterly & annually)

How has PRLD Current Ratio performed in the past?

The mean historical Current Ratio of Prelude Therapeutics Incorporated over the last ten years is 10.92. The current 7.04 Current Ratio has changed 6.34% with respect to the historical average. Over the past ten years (40 quarters), PRLD's Current Ratio was at its highest in in the March 2021 quarter at 29.38. The Current Ratio was at its lowest in in the March 2019 quarter at 0.

Prelude Therapeutics Incorporated (PRLD) Current Ratio by Quarter and Year

Discovering the peaks and valleys of Prelude Therapeutics Incorporated Current Ratio, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.

Prelude Therapeutics Incorporated (PRLD) Average Current Ratio

How has PRLD Current Ratio performed in the past?

The current Current Ratio of Prelude Therapeutics Incorporated (PRLD) is less than than its 3-year, less than than its 5-year, and less than than its 10-year historical averages

Prelude Therapeutics Incorporated (PRLD) Current Ratio vs. Peers

How is PRLD’s Current Ratio compared to its peers?

Prelude Therapeutics Incorporated’s Current Ratio is greater than Foghorn Therapeutics Inc. (4.77), less than Shattuck Labs, Inc. (7.96), greater than Monte Rosa Therapeutics, Inc. (6.03), less than Kymera Therapeutics, Inc. (8.55), greater than Nurix Therapeutics, Inc. (5.28), greater than C4 Therapeutics, Inc. (6.31), less than Eliem Therapeutics, Inc. (0), less than Cyteir Therapeutics, Inc. (21.89), less than Rezolute, Inc. (13.79), less than Molecular Partners AG (14.33), less than Mineralys Therapeutics, Inc. (8.55), less than AN2 Therapeutics, Inc. (9.75), less than Pharvaris N.V. (19.08), less than PepGen Inc. (8.47), greater than TCR2 Therapeutics Inc. (2.77), less than Revolution Medicines, Inc. (14.24), greater than Black Diamond Therapeutics, Inc. (5.55), greater than Atreca, Inc. (1.58), greater than Passage Bio, Inc. (5.15),

Build a custom stock screener for Prelude Therapeutics Incorporated (PRLD) and other stocks

One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like Prelude Therapeutics Incorporated using the financials and key metrics that matter to you in a single view.

The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:

Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.

Get your free trial here.

Prelude Therapeutics Incorporated (PRLD) and other stocks custom spreadsheet templates

The easiest way to analyze a company like Prelude Therapeutics Incorporated or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.

Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.

Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.